Federica Pericle

Was the Founder and Managing Director of Biotechnology Investment Opportunity (BIO) and has over 25 years’ experience in scientific, strategic and leadership positions within the biotechnology industry NIH, and academia. Prior to joining Chrysalis, Dr. Pericle was the President and CEO of Agilvax, Inc., a biotechnology company developing novel cancer therapies and vaccines for infection diseases. Dr. Pericle currently also serves as Analyst for Bluestar Investment Managers (www.bluestar-im.ch) managing the Onelife Fund fully dedicated to the life science sector (~$70MM).